Bill Text: CA SB639 | 2023-2024 | Regular Session | Amended
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Medical professionals: course requirements.
Spectrum: Moderate Partisan Bill (Democrat 8-1)
Status: (Passed) 2024-09-21 - Chaptered by Secretary of State. Chapter 336, Statutes of 2024. [SB639 Detail]
Download: California-2023-SB639-Amended.html
Bill Title: Medical professionals: course requirements.
Spectrum: Moderate Partisan Bill (Democrat 8-1)
Status: (Passed) 2024-09-21 - Chaptered by Secretary of State. Chapter 336, Statutes of 2024. [SB639 Detail]
Download: California-2023-SB639-Amended.html
|
Amended
IN
Senate
March 20, 2023 |
CALIFORNIA LEGISLATURE—
2023–2024 REGULAR SESSION
Senate Bill
No. 639
| Introduced by Senator Limón |
February 16, 2023 |
An act to amend Section 125275 of the Health and Safety Code, relating to Alzheimer’s disease.
LEGISLATIVE COUNSEL'S DIGEST
SB 639, as amended, Limón.
Alzheimer’s disease.
Existing law makes various findings and declarations regarding Alzheimer’s disease.
This bill would add additional findings and declarations regarding the impacts of Alzheimer’s disease and dementia over the next 20 years. years and encouraging the development of diagnostic hubs for Alzheimer’s disease. The bill would declare the purpose of the diagnostic hubs to be, among other things, to increase the training of health care professionals with respect to Alzheimer’s disease and other acquired brain impairments by expanding educational relationships that support primary care, develop thorough care plans, and improve diagnostics so that health care professionals have the requisite
training and expertise to know when to refer and feel comfortable with detection and diagnosis of Alzheimer’s disease and related dementia.
Digest Key
Vote: MAJORITY Appropriation: NO Fiscal Committee: NO Local Program: NOBill Text
The people of the State of California do enact as follows:
SECTION 1.
Section 125275 of the Health and Safety Code is amended to read:125275.
(a) The Legislature finds that Alzheimer’s disease, a devastating disease that destroys certain vital cells of the brain, affects more than 6,500,000 Americans. The Legislature also finds that the impacts of Alzheimer’s disease and dementia over the next 20 years will increase dramatically. Longer life expectancies and the aging of the large baby boom cohort will lead to an increase in the number and percentage of Californians who will be 65 years of age and older. Because the primary risk factor is older age, substantial increase is anticipated in the numbers of people who will be living with Alzheimer’s disease, and due to the higher prevalence of the Alzheimer’s in the Black and Latino/a/x communities, these communities will see their rates triple. The Legislature recognizes that the disease has serious emotional, financial, and social consequences for its victims and their families.(b) The Legislature recognizes that the cause of Alzheimer’s disease is presently unknown, and there is no established treatment which can cure, reverse, or stop the progression of Alzheimer’s disease. The Legislature also
recognizes that research is the only hope for victims and families. unknown. However, with significant state and federal investment, clinical treatments are being developed that can slow disease progression and offer the promise of more time. The Legislature finds that existing diagnostic and treatment centers have improved the quality of care available to the victims of Alzheimer’s disease and increased knowledge with respect to Alzheimer’s disease and related disorders. These centers provide clinical opportunities for research and facilitate the collection of essential data regarding Alzheimer’s disease and related disorders, while at the same time providing valuable services such as information and referral, counseling, and training to victims and their families. It is the intent of the Legislature, in
enacting this article, to encourage the establishment of geographically dispersed diagnostic and treatment centers hubs for Alzheimer’s disease within every postsecondary higher educational institution with a medical center, and to encourage research to discover the cause of, and a cure for, Alzheimer’s disease. as well as satellite locations that will serve regions without a postsecondary higher educational institution with a medical center, which will serve as diagnostic hubs for their regions.
(c) The functions of the
diagnostic and treatment centers
hubs shall be designed to serve all of the following purposes:
(1) To provide diagnostic and treatment services and improve the quality of care to victims of patients living with Alzheimer’s disease.
(2) To increase research by faculty and students in discovering the cause of, and a cure for, Alzheimer’s disease.
(3) To provide training, monitoring, consultation, and continuing education to the families of those who are affected by Alzheimer’s disease.
(4)
(2) To increase the training of health care professionals with respect to Alzheimer’s disease and other acquired brain impairments to the extent that the centers have the requisite expertise. by expanding educational relationships that support primary care, develop thorough care plans, and improve diagnostics so that health care professionals have the requisite training and expertise to know when to refer and feel comfortable with detection and diagnosis of Alzheimer’s disease and related dementia.
(3) To continue and expand upon the cognitive health assessment training and validated tool for Medi-Cal beneficiaries as outlined in Section 14132.171 of the Welfare and Institutions Code.
(4) To create capacity through the work of the hubs to secure access to new Alzheimer’s and related dementia clinical therapies coming to the market.
(d) The diagnostic and treatment centers may collaborate with the Statewide Resources Consultant designated pursuant to Section 4364 of the Welfare and Institutions Code, to the extent that the centers deem necessary in order to fulfill the functions set forth in subdivision (c).
hubs may collaborate with relevant state departments to provide, where relevant, expertise related to state or federal research, and training, monitoring, consultation, and continuing education to the families of those who are affected by Alzheimer’s disease.
